Amy S. Clark, MD, MSCE

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.

Description of Research Expertise

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications

Clark AS, Yau C, Wolf DM, Petricoin EF, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Albain KS, Tripathy D, Ellis ED, Forero-Torres A, Yung R, Han HS, Lang JE, Viscusi RK, Haley BB, Kemmer K, Elias AD, Nanda R, Boughey JC, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA,Alvarado M, Crane EP, Robinson P, Buxton M, Clennell JL, Paolini M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare AL, Matthews J, Berry S, Snail A, Melissa M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hilton NM, Yee D, Van 't Veer LJ, Berry DA, Esserman LJ, DeMichele AM: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2- positive breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications 12(1): 6428, November 2021 Notes: manuscript under revision.

Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ: Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol September 2021.

Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley D, Karuturi MS, Sanft T, Blau S, Hart L, Ma CX, Rugo HS, Purkayastha D, Moulder-Thompson S.: Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clinical Cancer Research August 2021 Notes: doi: 10.1158/1078-0432.CCR-20-2114. Online ahead of print.

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ.: Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell 39 : 989-998, July 2021.

Miller KD, Zhao F, Clark AS, Wilkinson G, Heineman T, Wolff A: BRACELET-1 (PrE0113): A Study To Assess Overall Response Rate By Inducing An Inflammatory Phenotype In Metastatic Breast Tumors With The Oncolytic Reovirus Pelareorep In Combination With Anti-PD-L1 Avelumab And Paclitaxel. ASCO Annual Meeting 2021 June 2021 Notes: Poster Presentation submitted for ASCO Annual Meeting 2021.

Chein AJ, Soliman H, Ewing C, Boughey JC, Campbell MJ, Rugo HS, Schwab R, Maure M, Wong J, Wallace A, Hieken TJ, Degnim AC, Albanien KS, Goodellas C, Stringer-Reasor E, Church A, Kalinsky K, Elias A, Mitri Z, Clark AS, Nanda R, Thomas A, Han H, Isaacs C, Lang JE, Yau C, Yee D, DeMichele AM, Perlmutter J, Hilton NM, Symmans WF, Melisko ME, van't Veer LJ, I-SPY 2 Consortium, Wilson A, Lu R, Asare SM, Sanil A, Berry DA, Esserman LJ: Evaluation of Intra-tumoral (IT) SD-101 and Pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 TRIAL. J Clin Oncol 39, June 2021 Notes: suppl 15; abstr 508 (Oral Presentation).

Takvorian SU, Parikh RB, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Full P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Miksad RA, Clip GS, Shulman LN, Mamtani E, Hubbard RA: Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer. ASCO Annual Meeting 2021 June 2021 Notes: Poster Presentation.

Clark AS, Elmi A, McAndrew N, Wileyto EP, Shih N, Feldman M, Rosen M, Savage J, Holmes R, DiNubile N, Berger TE, Schubert E, Matthai A, Volpe M, Shah PD, Matro J, Domchek S, Mankoff D, DeMichele A: Cell cycle synchronization: Biomarker analysis in a phase I trial of alternating ribociclib and paclitaxel in advanced breast cancer AACR Annual Meeting 2021 April 2021 Notes: Accepted for ePoster Presentation AACR Annual Meeting 2021.

McDonald ES, Pantel AR, Shah PD, Farwell MD, Clark AS, Doot RK, Pryma DA, Carlin SD.: In vivo visualization of PARP inhibitor pharmacodynamics. JCI Insight 8(8): 14692, Apr 2021.

Clark AS, Mahklin I, DeMichele A: Setting the Pick: Can PI3K inhibitors circumvent CDK 4/6 inhibitor resistance? Clinical Cancer Research January 2021.

back to top
Last updated: 11/11/2021
The Trustees of the University of Pennsylvania